graphic
abstract
highlight
monoclon
antibodi
block
interact
ebolaviru
host
receptor
crossneutr
protect
ebov
sudv
rodent
new
zmapp
version
includ
protect
guinea
pig
ebov
sudv
specif
gp
mutat
expos
epitop
crossneutr
mab
brief
howel
et
al
examin
mab
bind
ebolaviru
receptorbind
site
find
protect
ebov
sudv
combin
two
zmapp
tm
compon
antibodi
cocktail
retain
ebov
protect
similar
zmapp
tm
extend
protect
sudv
specif
glycoprotein
mutat
enhanc
exposur
crossneutr
epitop
describ
previou
effort
identifi
crossneutr
antibodi
receptorbind
site
rb
ebolaviru
glycoprotein
unsuccess
larg
rb
occlud
viral
surfac
report
monoclon
antibodi
target
uniqu
expos
epitop
within
rb
crossneutr
ebola
ebov
sudan
sudv
lesser
extent
bundibugyo
virus
show
protect
ebov
sudv
mice
guinea
pig
antibodi
cocktail
zmapp
tm
remark
effect
ebov
zair
crossneutr
ebolavirus
replac
one
zmapp
tm
compon
retain
antiebov
efficaci
extend
breadth
protect
sudv
therebi
gener
crossprotect
antibodi
cocktail
addit
report
sever
mutat
base
ebolaviru
glycoprotein
enhanc
bind
crossreact
antibodi
find
import
implic
panebolaviru
vaccin
develop
defin
broadli
protect
antibodi
cocktail
filovirus
caus
agent
sever
hemorrhag
fever
human
nonhuman
primat
nhp
kuhn
et
al
member
famili
filovirida
includ
two
marburgvirus
marburg
viru
marv
ravn
viru
ravv
five
ebolavirus
ebola
viru
ebov
sudan
viru
sudv
bundibugyo
viru
bdbv
reston
viru
restv
forest
viru
tafv
kuhn
et
al
ebov
zair
caus
largest
number
outbreak
includ
ebov
diseas
evd
epidem
led
case
death
due
higher
frequenc
outbreak
caus
ebov
effort
toward
vaccin
therapeut
develop
focus
agent
sever
studi
shown
remark
efficaci
antibodi
therapeut
ebov
marzi
et
al
oling
et
al
pettitt
et
al
qiu
et
al
qiu
et
al
qiu
et
al
qiu
et
al
howev
recent
bound
et
al
flyak
et
al
frei
et
al
holtsberg
et
al
keck
et
al
develop
crossprotect
monoclon
antibodi
mab
target
multipl
speci
ebolaviru
lag
behind
filoviru
surfac
glycoprotein
compris
disulfidelink
subunit
primari
target
vaccin
immunotherapeut
marzi
feldmann
crystal
structur
trimer
ebov
gp
spike
henceforth
term
gp
complex
lee
et
al
neutral
mab
deriv
evd
human
survivor
maruyama
et
al
well
sudv
gp
complex
neutral
mous
mab
dia
et
al
reveal
key
mechan
neutral
three
subunit
form
chalicelik
structur
wrap
around
n
terminu
form
base
chalic
lee
et
al
contact
residu
within
base
neutral
viru
block
viral
fusion
endosom
membran
dia
et
al
lee
et
al
administ
prophylact
hr
infect
protect
guinea
pig
lethal
ebov
challeng
parren
et
al
howev
singl
studi
protect
ebov
nhp
test
dose
regimen
oswald
et
al
sever
recent
studi
reveal
effect
postexposur
protect
ebov
primat
requir
cocktail
mab
pettitt
et
al
qiu
et
al
qiu
et
al
combin
mab
interferon
alpha
ifna
qiu
et
al
qiu
et
al
test
variou
combin
guinea
pig
model
ebov
infect
identifi
highli
effect
cocktail
three
ebovspecif
mab
known
zmapp
tm
zmapp
tm
show
efficaci
nhp
treatment
initi
late
day
postinfect
dpi
singleparticl
electron
microscopi
em
reconstruct
gp
complex
individu
zmapptm
compon
reveal
two
site
vulner
ebov
gp
elucid
structur
basi
remark
efficaci
murin
et
al
three
compon
zmapp
tm
target
epitop
share
base
chalic
near
interfac
wherea
bind
highli
glycosyl
domain
top
gp
molecul
known
glycan
cap
davidson
et
al
murin
et
al
combin
base
glycan
cap
binder
thu
far
appear
effect
ebov
antibodi
viru
specif
clear
paradigm
appli
broadli
protect
immunotherapeut
although
epitop
engag
ebovspecif
sudvspecif
overlap
ten
residu
dia
et
al
lee
et
al
base
binder
crossreact
ebolavirus
neutral
antibodi
target
receptorbind
site
rb
describ
sever
virus
includ
influenza
lee
wilson
hiv
georgiev
et
al
sar
sever
acut
respiratori
syndrom
coronavirus
coughlin
prabhakar
chikungunya
viru
van
duijlricht
et
al
howev
neutral
antibodi
identifi
would
target
rb
within
ebolaviru
glycoprotein
filoviru
rb
consist
rel
expos
hydrophil
crest
hydrophob
trough
expos
marburgviru
occlud
glycan
cap
ebov
gp
wang
et
al
rbsbind
mab
recent
identifi
marburgviru
shown
bind
rb
trough
antibodi
also
bind
ebov
gp
glycan
cap
proteolyt
remov
thermolysin
process
mimic
cathepsinmedi
cleavag
endosom
contrast
antibodi
report
date
bind
promin
crest
region
rb
recent
report
panebolaviru
panfiloviru
antibodi
includ
two
broadli
neutral
mab
isol
mice
macaqu
immun
mixtur
engin
glycoprotein
ebov
sudv
marv
boost
viruslik
particl
vlp
three
virus
holtsberg
et
al
keck
et
al
contrast
base
binder
antibodi
bind
apex
gp
trimer
either
inner
chalic
glycan
cap
report
one
mab
bind
tip
rb
crest
block
interact
ebov
gp
endosom
receptor
niemannpick
em
reconstruct
complex
ebov
gp
show
uniqu
asymmetr
mode
engag
singl
antibodi
per
trimer
neutral
ebov
sudv
lesser
extent
bdbv
protect
mice
guinea
pig
lethal
challeng
ebov
sudv
furthermor
replac
one
base
binder
zmapp
tm
retain
potenc
cocktail
toward
ebov
expand
protect
breadth
cocktail
includ
sudv
bind
expos
region
filoviru
rb
recent
describ
sever
macaquederiv
panebolaviru
mab
keck
et
al
one
mab
neutral
ebov
sudv
show
signific
efficaci
mice
administ
two
dose
one
day
challeng
one
dpi
keck
et
al
studi
suggest
target
conform
epitop
share
among
ebolavirus
low
level
crossreact
marv
keck
et
al
order
defin
epitop
use
alanin
scan
approach
bind
evalu
shotgun
mutagenesi
mutat
librari
ebov
gp
target
residu
individu
mutat
human
cell
transfect
entir
librari
array
format
one
clone
per
well
figur
assess
reactiv
highthroughput
flow
cytometri
epitop
map
identifi
ebov
gp
residu
critic
bind
figur
alanin
substitut
residu
reduc
bind
wildtyp
respect
suggest
residu
constitut
key
contact
site
greatest
energet
contribut
bind
figur
contrast
bind
two
panebolaviru
antibodi
keck
et
al
affect
mutat
figur
put
epitop
posit
previous
describ
region
crestandtrough
morpholog
bornholdt
et
al
hashiguchi
et
al
within
rb
constitut
tip
hydrophil
crest
red
dot
outlin
figur
interact
loop
endosom
filoviru
receptor
wang
et
al
contrast
expos
tip
crest
trough
line
hydrophob
residu
occlud
loop
within
glycan
cap
black
dot
outlin
figur
occlus
explain
troughbind
mab
bind
neutral
ebov
unless
glycan
cap
remov
proteolysi
interestingli
bind
well
ebov
gp
bind
moder
enhanc
alanin
substitut
mutat
delet
three
four
glycosyl
site
glycan
cap
figur
suggest
glycan
may
modestli
interfer
bind
nonetheless
data
show
repres
prototyp
panebolaviru
antibodi
recogn
uniqu
expos
epitop
within
rb
crest
region
highli
conserv
among
ebolaviru
speci
three
residu
critic
bind
ident
among
ebolavirus
figur
overlay
crystal
structur
ebov
gp
lee
et
al
structur
thermolysincleav
gp
gp
cl
bornholdt
et
al
wang
et
al
sudv
gp
dia
et
al
show
high
structur
conserv
within
region
promin
exposur
residu
surfac
gp
cl
figur
sudv
gp
figur
one
three
residu
put
epitop
match
ebov
marv
figur
region
still
show
high
degre
conform
similar
ebov
marv
three
critic
ebov
residu
overlay
well
marv
figur
may
explain
low
affin
marv
gp
previous
report
keck
et
al
ebovneutr
antibodi
lee
et
al
parren
et
al
murin
et
al
qiu
et
al
bind
overlap
epitop
base
gp
trimer
consist
residu
base
figur
contrast
appear
bind
apex
trimer
glycan
cap
trimer
center
figur
therefor
repres
distinct
class
neutral
antibodi
addit
epitopemap
inform
lossoffunct
analysi
alaninescan
experi
reveal
strike
differ
gpbind
pattern
basebind
apexbind
class
neutral
bind
base
binder
individu
mutant
remain
consist
wildtyp
gp
figur
sever
singlealanin
mutat
gp
dramat
enhanc
effect
high
bind
figur
amino
acid
form
base
alanin
mutat
residu
increas
bind
gp
figur
tabl
residu
hydrophob
highli
network
surfac
expos
figur
tabl
addit
base
residu
mutat
within
furin
cleavag
site
separ
volchkov
et
al
also
led
human
cell
express
mutat
librari
test
reactiv
mab
use
intellicyt
flow
cytomet
typic
reactiv
pattern
red
well
shown
repres
assay
plate
eight
posit
wildtyp
ebov
gp
eight
neg
mocktransfect
control
well
includ
plate
b
librari
test
reactiv
clone
bind
rel
wildtyp
wt
ebov
gp
yet
reactiv
control
mab
initi
identifi
critic
bind
c
mutat
three
individu
residu
reduc
bind
red
bar
littl
effect
bind
gray
bar
keck
et
al
bar
repres
mean
rang
least
two
replic
data
point
bind
residu
shown
red
crystal
structur
ebov
gp
glycan
cap
shown
cyan
attach
point
nlink
glycan
orang
core
shown
purpl
part
seen
yellow
rb
crest
shown
red
outlin
occlud
trough
region
shown
black
outlin
e
sequenc
homolog
filovirus
within
rb
crest
region
contain
put
epitop
ident
sequenc
among
ebolaviru
speci
ebolaviru
marburgviru
shown
red
bind
site
box
fh
ebov
gp
monom
depict
cartoon
overlay
gp
cl
f
sudv
gp
g
marv
ravn
gp
h
put
critic
ebov
contact
made
shown
stick
red
overlaid
correspond
contact
residu
overlay
structur
green
increas
bind
figur
tabl
alanin
mutagenesi
scan
sever
crossreact
apexbind
antibodi
holtsberg
et
al
keck
et
al
also
reveal
similar
enhanc
bind
alanin
mutant
enhanc
bind
tabl
data
suggest
specif
mutat
gp
base
may
global
impact
exposur
crossreact
epitop
head
domain
find
may
major
implic
design
panebolaviru
vaccin
character
bind
ebov
gp
fab
complex
gpdmuc
analyz
negativestain
em
bind
locat
reveal
epitop
consist
crest
residu
deriv
mutagenesi
studi
class
averag
suggest
one
fab
bind
gp
trimer
figur
figur
bind
one
fab
per
trimer
also
confirm
size
exclus
chromatographymultiangl
light
scatter
secmal
analysi
figur
like
bind
orient
proxim
axi
preclud
addit
fab
bind
contrast
previous
character
glycancapbind
antibodi
bind
nearbi
region
greater
occup
two
three
fab
per
gp
trimer
murin
et
al
figur
although
sever
attempt
made
gener
reconstruct
bind
gp
data
fail
converg
interpret
model
suggest
crest
epitop
flexibl
use
sever
assay
evalu
crossneutr
activ
multipl
ebolavirus
assay
includ
replicationincompet
vesicular
stomat
virus
vsv
pseudotyp
filoviru
gp
express
luciferas
vsvgpluc
well
replicationcompet
vsv
pseudotyp
express
gfp
vsvgpgfp
wildtyp
live
viru
first
assay
identifi
directentri
inhibitor
antibodi
inhibit
either
entri
stage
viral
replic
identifi
second
assay
live
viru
shown
figur
effect
neutral
entri
vsvpseudotyp
ebov
sudv
half
maxim
effect
concentr
ec
valu
mgml
respect
also
examin
whether
neutral
depend
bival
bind
full
immunoglobulin
ig
g
whether
fab
fragment
would
also
mediat
neutral
ebov
entri
effect
inhibit
fab
ec
similar
full
igg
howev
neutral
potenc
fab
toward
sudv
reduc
compar
full
igg
figur
also
effect
neutral
replicationcompet
vsv
pseudotyp
ebov
sudv
tafv
figur
show
low
neutral
activ
toward
vsvbdbv
gpgfp
neutral
plateau
leav
nonneutr
subset
infecti
virion
remain
figur
test
neutral
activ
authent
wildtyp
ebov
sudv
bdbv
use
plaqu
reduct
neutral
prnt
assay
biosafeti
level
contain
highest
neutral
activ
observ
sudv
higher
concentr
requir
effect
neutral
wildtyp
ebov
bdbv
respect
figur
expect
neutral
marv
figur
previou
report
show
mab
target
trough
region
rb
poorli
neutral
vsvebov
gp
neutral
pseudotyp
viru
cleavag
thermolysin
vsvebov
gp
cl
mimic
cathepsin
cleavag
endosom
bornholdt
et
al
flyak
et
al
hashiguchi
et
al
end
test
whether
crest
binder
could
also
neutral
endosom
form
viru
whether
proteolyt
remov
glycan
cap
mucinlik
domain
mld
impact
neutral
potenc
shown
figur
neutral
vsvebov
gp
cl
vsvsudv
gp
cl
nearli
effect
vsv
express
fulllength
gp
compar
figur
suggest
cathepsin
cleavag
may
expos
site
convers
increas
partial
neutral
bdbv
observ
upon
thermolysin
cleavag
figur
given
locat
epitop
antibodi
dramat
increas
neutral
efficaci
upon
thermolysin
cleavag
hypothes
block
bind
cleav
ebov
gp
gp
cl
endosom
receptor
bind
flagtag
solubl
domain
c
biotinyl
vsvebov
gp
cl
immobil
streptavidinco
plate
test
presenc
absenc
shown
figur
exhibit
concentrationdepend
inhibit
bind
gp
cl
suggest
inhibit
gp
bind
endosom
receptor
one
like
mechan
action
use
biolay
interferometri
bli
measur
affin
bind
ebov
sudv
bdbv
gp
ectodomain
gpdtm
bound
protein
g
sensor
expos
rang
gpdtm
concentr
figur
associ
dissoci
ebov
sudv
gpdtm
fit
bind
model
figur
k
ebov
gpdtm
calcul
nm
k
associ
rate
sec
k
dissoci
rate
affin
sudv
gpdtm
slightli
higher
k
nm
k
sec
k
affin
ebov
sudv
gpdtm
also
analyz
addit
experi
use
antihuman
fccoat
sensor
k
valu
found
similar
interestingli
bind
bdbv
gpdtm
best
describ
bind
model
two
dissoci
constant
k
nm
k
nm
figur
initi
associ
within
rang
ebov
gpdtm
sudv
gpdtm
k
sec
second
associ
step
slower
k
sec
dissoci
rate
bdbv
gpdtm
fastest
among
three
protein
k
k
collect
kinet
analysi
offer
biophys
explan
differenti
neutral
profil
three
virus
exhibit
potent
neutral
ebov
sudv
consist
high
affin
glycoprotein
vitro
nanomolar
rang
k
modest
neutral
activ
bdbv
consist
poorer
bind
profil
toward
gp
differ
bind
ebovsudv
bdbv
gp
evid
biphas
dissoci
phase
bdbv
domin
dissoci
rate
k
two
order
magnitud
faster
ebov
sudv
gp
previous
report
efficaci
mous
model
ebov
administ
two
dose
start
immedi
infect
keck
et
al
expand
studi
postexposur
treatment
ebov
model
recent
develop
mous
model
sudv
first
evalu
delay
administr
singl
dose
group
ten
mice
infect
plaqueform
unit
pfu
mouseadapt
ebov
maebov
bray
et
al
treat
singl
intraperiton
ip
inject
mgkg
mg
per
mous
either
dpi
singl
inject
dpi
led
full
protect
lethal
challeng
p
determin
manelcox
method
delay
treatment
day
day
peak
viremia
result
p
p
protect
respect
figur
consist
surviv
data
mice
treat
dpi
show
weight
loss
sign
diseas
figur
mice
treat
dpi
lost
maximum
bodi
weight
respect
compar
weight
loss
control
group
milder
clinic
sign
diseas
observ
figur
evalu
dose
respons
treat
mice
dpi
mgkg
mg
per
mous
pb
control
studi
mgkg
provid
full
protect
p
mice
receiv
mgkg
surviv
challeng
p
figur
pbstreat
mice
lost
bodi
weight
succumb
infect
mice
treat
show
less
weight
loss
less
sever
diseas
determin
health
score
figur
data
clearli
indic
postexposur
efficaci
rel
low
dose
efficaci
test
mice
gene
ifnaifnb
interferon
beta
receptor
knock
ifnabr
group
seven
ifnabr
mice
infect
pfu
sudv
follow
ip
inject
mgkg
antisudv
gp
mab
dpi
dpi
control
group
six
mice
receiv
treatment
infect
sudvspecif
fulli
protect
mice
minim
weight
loss
sign
diseas
figur
five
seven
mice
treat
protect
lethal
challeng
effect
averag
weight
loss
health
score
appar
figur
efficaci
also
examin
guinea
pig
use
guineapigadapt
ebov
sudv
gpaebov
gpasudv
respect
volchkov
et
al
wong
et
al
four
group
six
guinea
pig
challeng
either
ld
median
lethal
dose
gpasudv
gpaebov
follow
singl
ip
inject
mg
mgkg
vehicl
control
dpi
anim
monitor
day
weight
chang
day
surviv
singl
inject
protect
guinea
pig
gpasudv
challeng
control
succumb
infect
within
day
p
figur
control
lost
bodi
weight
gpasudv
challeng
weight
loss
sign
diseas
observ
among
anim
figur
dpbstreat
guinea
pig
infect
gpaebov
succumb
infect
within
day
two
six
anim
surviv
challeng
remain
die
dpi
p
figur
median
surviv
day
control
group
day
group
control
anim
lost
weight
die
anim
initi
gain
weight
follow
moder
weight
loss
day
postchalleng
figur
partial
protect
ebov
consist
previou
report
indic
antibodi
cocktail
requir
effect
postexposur
protect
ebov
guinea
pig
nhp
zmapp
tm
consist
two
base
binder
glycan
cap
binder
select
test
nhp
base
signific
partial
protect
guinea
pig
four
six
administ
dpi
base
aforement
studi
hypothes
replac
one
zmapp
tm
compon
would
lead
effect
ebov
cocktail
also
protect
sudv
select
mab
replac
sinc
bind
epitop
close
overlap
epitop
davidson
et
al
murin
et
al
first
test
whether
alon
mg
cocktail
mg
would
protect
gpasudv
administ
dpi
gpasudvinfect
control
anim
die
within
day
anim
five
six
anim
treat
cocktail
surviv
challeng
figur
protect
highli
signific
p
treatment
group
compar
control
anim
treat
exhibit
weight
loss
control
anim
lost
averag
bodi
weight
figur
anim
treat
cocktail
also
show
weight
loss
averag
figur
fatal
case
group
lost
bodi
weight
die
day
postinfect
cocktail
consist
also
test
gpaebov
model
four
six
anim
treat
singl
dose
mg
cocktail
mg
compon
dpi
surviv
challeng
control
anim
succumb
infect
within
day
p
figur
control
anim
lost
averag
weight
averag
weight
within
cocktailtr
group
show
steadi
increas
dpi
figur
two
cocktailtr
anim
die
one
lost
bodi
weight
day
death
dpi
second
anim
actual
gain
bodi
weight
die
day
comparison
figur
show
compil
surviv
weight
loss
data
three
studi
perform
zmapp
tm
mg
per
anim
n
surviv
rate
guinea
pig
cocktail
well
within
rang
protect
afford
zmapp
tm
shown
report
previous
devast
evd
epidem
west
africa
sober
remind
global
threat
filoviru
infect
outbreak
reach
unpreced
dimens
despit
fact
major
effort
develop
vaccin
therapeut
past
decad
focus
ebolaviru
caus
epidem
given
uncertainti
natur
reservoir
zoonot
dynam
filovirus
imposs
predict
speci
locat
futur
outbreak
thu
broadli
protect
vaccin
therapeut
urgent
need
cope
emerg
threat
recent
report
indic
mab
gp
effect
postexposur
treatment
ebolaviru
hemorrhag
fever
pettitt
et
al
qiu
et
al
zmapp
tm
cocktail
three
mab
ebov
gp
among
advanc
therapeut
candid
exhibit
remark
efficaci
symptomat
ebovinfect
nhp
howev
immunotherapeut
candid
speci
specif
mostli
target
ebov
zair
accord
current
dogma
field
combin
antibodi
requir
effect
control
ebov
infect
antibodi
current
cocktail
includ
target
base
trimer
gp
well
bind
apex
trimer
glycan
cap
murin
et
al
recent
engin
bispecif
antibodi
target
gp
base
ebov
sudv
shown
provid
postexposur
protect
mice
frei
et
al
despit
structur
overlap
sudvspecif
ebovspecif
date
crossbind
antibodi
target
gp
base
epitop
canon
igg
framework
describ
thu
antibodi
cocktail
expand
neutral
protect
breadth
like
engag
novel
epitop
recent
identifi
set
panebolaviru
panfiloviru
mab
target
phylogenet
conserv
site
within
glycan
cap
core
includ
two
mab
effect
crossneutr
ebov
sudv
two
diverg
filovirus
holtsberg
et
al
keck
et
al
report
full
character
panebolaviru
mab
demonstr
target
uniqu
expos
epitop
within
rb
convey
postexposur
protect
ebov
sudv
receptorbind
unit
filoviru
gp
oceanwav
morpholog
recess
trough
rise
crest
bornholdt
bornholdt
et
al
hashiguchi
et
al
contrast
wave
crest
strand
connect
loop
ebolaviru
gp
hydrophil
contain
basic
residu
undergo
electrostat
interact
filoviru
host
receptor
bornholdt
et
al
wang
et
al
recess
trough
occlud
specif
interact
residu
glycan
cap
hydrophob
line
trough
block
access
surfac
ebov
gp
cathepsinmedi
cleavag
within
endosom
remov
glycan
cap
residu
within
ebolaviru
gp
trough
unmask
specif
interact
bornholdt
et
al
krishnan
et
al
find
provid
structur
explan
observ
marvneutr
antibodi
bind
fulllength
marv
gp
trough
appar
expos
bind
neutral
ebov
thermolysin
cleavag
remov
glycan
cap
contrast
tip
crest
access
surfac
gp
trimer
bornholdt
et
al
hashiguchi
et
al
alaninescan
mutagenesi
analysi
reveal
posit
tip
crest
critic
residu
bind
bornholdt
et
al
recent
demonstr
mutat
alanin
significantli
reduc
bind
gp
cl
mutat
residu
glutam
acid
complet
abrog
gp
interact
suggest
basic
residu
involv
receptor
bind
bornholdt
et
al
moreov
recent
solv
xray
crystal
structur
gp
cl
domain
c
protein
complex
reveal
loop
domain
c
directli
contact
basic
crest
wang
et
al
show
bind
specif
block
interact
gp
cl
late
corti
et
al
also
report
ebovspecif
antibodi
bind
ebov
gp
glycan
cap
rb
region
block
gp
interact
thu
repres
distinct
crossneutr
antibodi
bind
expos
epitop
within
ebolaviru
rb
neutral
viru
least
part
blockad
receptor
interact
primari
amino
acid
sequenc
crest
region
highli
conserv
among
ebolavirus
modestli
homolog
ebolavirus
marburgvirus
tip
crest
includ
bind
site
also
show
high
structur
homolog
ebov
sudv
lesser
extent
c
three
group
ifnabr
mice
infect
pfu
sudv
one
group
n
receiv
two
ip
inject
dpi
second
group
receiv
dpi
third
group
left
untreat
mice
monitor
day
surviv
weight
chang
sign
diseas
ebov
marv
gp
effect
neutral
ebov
sudv
exhibit
partial
neutral
bdbv
previou
result
indic
bind
bdbv
gp
elisa
ec
compar
ebov
sudv
keck
et
al
howev
kinet
analysi
report
show
rapid
rate
bdbv
gp
provid
possibl
explan
low
neutral
activ
toward
bdbv
amino
acid
sequenc
ebov
bdbv
gp
crest
region
differ
posit
glutam
acid
ebov
versu
aspart
acid
bdbv
prolin
ebov
versu
alanin
bdbv
alaninescan
analysi
mutat
ebov
gp
alter
bind
wildtyp
respect
howev
possibl
residu
influenc
posit
key
residu
part
epitop
directli
lower
energet
level
captur
cellsurfac
stain
assay
neutral
vsv
pseudotyp
tafv
gp
also
differ
ebov
gp
crest
residu
bdbv
alanin
valin
posit
respect
nonetheless
effect
neutral
virul
ebolavirus
ebov
sudv
interest
featur
asymmetr
bind
gp
contrast
antibodi
zmapp
tm
compon
murin
et
al
lee
et
al
class
averag
analysi
negativestain
em
fab
bound
gpdmuc
reveal
bind
stoichiometri
one
fab
per
trimer
posit
em
studi
consist
mutat
analysi
togeth
result
suggest
mab
bind
angl
pose
bind
top
gp
well
perpendicular
plane
viral
membran
murin
et
al
although
quantit
establish
solut
studi
singl
fab
capabl
bind
even
satur
concentr
seem
reason
emderiv
imag
angl
approach
singl
fab
occlud
potenti
bind
site
two
subunit
studi
requir
elucid
implic
bind
morpholog
neutral
vivo
efficaci
tantal
possibl
fewer
igg
molecul
bind
gp
trimer
igg
averag
lower
requir
occup
could
theori
provid
therapeut
advantag
less
antibodi
would
requir
neutral
render
igg
less
suscept
decoy
antigen
sgp
gp
spike
defect
particl
exampl
studi
perform
antiebov
equin
ig
clearli
show
rapid
reduct
ebovspecif
equin
igg
titer
peak
viremia
nhp
total
equin
igg
titer
remain
constant
jahrl
et
al
suggest
high
antibodi
consumpt
infect
singlesit
occup
could
also
potenti
leav
gp
surfac
expos
mabgp
complex
provid
addit
opportun
engag
epitop
antibodi
cocktail
epitop
access
bind
probabl
entir
free
steric
hindranc
previou
report
indic
zmapp
tm
n
dpi
challeng
perform
ld
gpasudv
gpaebov
indic
surviv
monitor
dpi
weight
monitor
day
dpi
bind
gp
slightli
increas
remov
mld
glycan
cap
keck
et
al
data
figur
show
neutral
viru
carri
gp
cl
effect
fulllength
gp
interestingli
mutagenesi
studi
reveal
contrast
bind
substanti
enhanc
certain
residu
within
base
gp
n
terminu
mutat
alanin
mutat
also
increas
bind
crossreact
antibodi
previous
report
holtsberg
et
al
keck
et
al
residu
mostli
hydrophob
buri
structur
suggest
singlepoint
mutat
within
base
may
loosen
apex
expos
crossreact
epitop
find
may
import
implic
develop
panebolaviru
vaccin
mutat
incorpor
vaccin
improv
potenc
breadth
protect
efficaci
studi
mice
guinea
pig
show
high
therapeut
valu
full
protect
ebov
infect
observ
dpi
littl
mg
per
mous
lower
dose
mg
per
mous
show
partial
signific
protect
smallscal
studi
ifnabr
mice
show
protect
lethal
sudv
challeng
administ
dpi
data
show
compar
well
postexposur
efficaci
dpi
ebovspecif
mab
report
qiu
et
al
expand
breadth
protect
includ
sudv
guinea
pig
model
ebov
infect
consid
substanti
stringent
model
screen
therapeut
cross
et
al
parren
et
al
qiu
et
al
particularli
test
therapeut
dpi
model
particularli
stringent
good
predict
valu
efficaci
nhp
recent
wong
et
al
also
report
develop
guinea
pig
model
sudv
infect
wong
et
al
gpasudv
caus
uniformli
lethal
infect
major
hallmark
sudv
infect
includ
lymphadenopathi
increas
liver
enzym
activ
coagul
abnorm
wong
et
al
use
model
present
studi
evalu
efficaci
singl
inject
mg
dpi
fulli
protect
guinea
pig
gpasudv
infect
sign
diseas
suggest
alon
may
suffici
control
sudv
infect
date
sudv
antibodi
test
nhp
studi
thu
known
protect
rodent
model
relat
efficaci
sudv
nhp
contrast
ebov
guinea
pig
model
protect
level
dpi
total
dose
mg
good
indic
efficaci
nhp
fact
zmapp
tm
cocktail
fulli
protect
nhp
dpi
select
base
partial
efficaci
dpi
guinea
pig
gpaebovinfect
guinea
pig
protect
two
six
anim
administ
dpi
protect
level
statist
signific
lower
report
protect
level
dpi
afford
qiu
et
al
data
suggest
alon
may
suffici
sudv
effici
protect
ebov
would
requir
cocktail
given
target
overlap
epitop
murin
et
al
reason
may
good
candid
replac
led
cocktail
protect
five
six
guinea
pig
sudv
four
six
anim
ebov
level
protect
ebov
compar
histor
efficaci
data
zmapp
tm
figur
data
demonstr
cocktail
effect
zmapp
tm
ebov
expand
breadth
protect
includ
sudv
efficaci
cocktail
must
test
futur
nhp
studi
howev
data
posit
strong
candid
compon
panebolaviru
therapeut
cocktail
antibodi
product
produc
cell
transfect
plasmid
encod
igh
igl
use
polyethylenimin
polysci
purifi
protein
chromatographi
describ
previous
keck
et
al
zmapp
tm
product
n
benthamiana
plant
genet
modifi
produc
homogen
mammalian
nglycan
gngn
glycoform
grown
week
enclos
growth
room
c
use
vacuum
infiltr
describ
previous
seven
day
later
mab
extract
leaf
tissu
purifi
via
protein
chromatographi
endotoxin
remov
use
acrodisc
unit
mustang
q
membran
pall
life
scienc
fab
product
igg
incub
papain
hr
c
reaction
quench
mm
iodoacetamid
fc
portion
remov
via
protein
affin
fab
purifi
via
sec
alaninescan
mutagenesi
express
construct
fulllength
ebov
gp
strain
davidson
et
al
chang
residu
alanin
alanin
residu
serin
creat
librari
clone
repres
individu
point
mutant
cover
residu
clone
individu
array
plate
transfect
cell
allow
express
hr
cell
incub
primari
antibodi
secondari
antibodi
jackson
immunoresearch
laboratori
wash
cellular
fluoresc
detect
use
intellicyt
highthroughput
flow
cytomet
intellicyt
background
fluoresc
determin
vectortransfect
control
cell
mab
reactiv
mutant
gp
clone
calcul
rel
wildtyp
gp
reactiv
subtract
signal
mocktransfect
control
normal
signal
wildtyp
gptransfect
control
mutat
residu
within
clone
identifi
critic
test
mab
epitop
support
reactiv
mab
support
reactiv
control
ebov
mab
counterscreen
facilit
exclus
gp
mutant
local
misfold
express
defect
detail
algorithm
use
interpret
shotgun
mutagenesi
data
describ
elsewher
patent
applic
davidson
doranz
cell
line
obtain
atcc
vero
cell
maintain
dmem
life
technolog
supplement
fetal
bovin
serum
fb
atlanta
biolog
penicillinstreptomycin
life
technolog
vero
cell
grown
eagl
minim
essenti
medium
emem
corn
supplement
fb
penicillinstreptomycin
cell
line
maintain
humidifi
c
co
incub
negativestain
em
studi
ebov
gpdmuc
individu
purifi
ebov
gpdmuc
combin
molar
excess
fab
incub
overnight
c
complex
purifi
sec
column
ge
healthcar
equilibr
trisbuff
salin
tb
complex
deposit
onto
carbonco
copper
mesh
grid
subsequ
stain
uranyl
format
grid
load
tecnai
spirit
imag
use
tietz
cmo
camera
magnif
nomin
defocu
mm
micrograph
collect
automat
use
leginon
suloway
et
al
process
within
appion
lander
et
al
dogpick
use
automat
pick
particl
raw
micrograph
place
stack
initi
referencefre
classif
undertaken
xmipp
sorzano
et
al
particl
correspond
ebov
gpdmuc
bound
eg
nois
amorph
particl
remov
point
result
final
stack
particl
remain
particl
process
two
subsequ
round
referencefre
classif
relion
schere
result
final
particl
count
approxim
half
final
class
averag
identifi
complex
ebov
gpdmuc
bound
imag
creat
ucsf
chimera
adob
photoshop
determin
absolut
molecular
weight
ebov
gpdmuc
first
perform
secmal
use
conjug
analysi
account
glycan
content
determin
number
fab
molecul
bound
ebov
gpdmuc
trimer
secmal
repeat
ebov
gpdmuc
complex
excess
fab
hr
room
temperatur
superdex
sec
column
coupl
line
follow
calibr
detector
minidawn
treo
mal
detector
wyatt
corpor
optilab
trex
refract
index
ri
detector
wyatt
corpor
astra
vi
softwar
wyatt
corpor
use
combin
measur
determin
absolut
molar
mass
elut
protein
two
differ
neutral
assay
base
pseudotyp
recombin
vsvexpress
filoviru
gp
use
replicationdefect
recombin
indiana
vsv
rvsv
gpluc
express
firefli
luciferas
replicationcompet
rvsv
express
gfp
rvsvgfp
rvsvgp
luciferas
pseudotyp
assay
pseudotyp
virus
gener
base
modif
previous
publish
method
whitt
cell
confluenc
transfect
plasmid
encod
ebov
gp
marv
gp
sudv
gp
use
fugen
hd
promega
accord
manufactur
protocol
next
day
cell
infect
rvsvdgp
pseudotyp
kerafast
moi
viru
wash
hr
dpb
next
day
supernat
collect
clarifi
centrifug
titer
pseudotyp
viru
cell
transfect
sixwel
plate
pcagg
vsvg
kerafast
hr
serial
dilut
vsvebovgpluc
vsvsudvgpluc
pseudotyp
ad
well
hr
addit
agar
dmem
next
day
well
fix
glutaraldehyd
min
remov
agar
stain
crystal
violet
count
plaqu
detail
luciferas
assay
determin
vsvgpluc
infect
previous
describ
keck
et
al
data
fit
curv
use
graphpad
prism
percent
neutral
calcul
base
well
contain
viru
rvsv
gpgfp
assay
rvsv
express
egfp
well
ebov
marv
gp
place
vsvg
describ
previous
ng
et
al
wong
et
al
rvsv
bear
tafv
sudv
gp
bdbv
gpdmuc
gener
method
vsv
particl
contain
cleav
gp
gp
cl
gener
incub
rvsvgp
thermolysin
mgml
hr
c
follow
treatment
phosphoramidon
mm
reaction
mixtur
use
immedi
infect
rvsv
measur
count
egfpposit
cell
hr
postinfect
use
cellinsight
autom
microscop
onboard
softwar
thermo
scientif
neutral
experi
serial
dilut
mab
incub
rvsvgp
hr
room
temperatur
monolay
vero
cell
seed
plate
inocul
mabviru
mixtur
triplic
incub
c
overnight
infect
score
hr
hr
postinfect
enumer
egfp
cell
normal
noantibodi
control
taken
repres
prnt
assay
antibodi
indic
concentr
incub
pfu
ebov
sudv
bonifac
c
co
humid
hr
mixtur
ad
vero
cell
sixwel
plate
incub
hr
cell
overlaid
mixtur
one
part
agaros
seakem
one
part
eagl
basal
medium
ebm
mm
hepe
buffer
dfb
incub
c
co
humid
second
overlay
contain
neutral
red
ad
day
later
plate
incub
overnight
plaqu
count
follow
day
percent
neutral
determin
compar
control
well
thermolysincleav
vsvgp
rvsvgp
cl
incub
functionalspacerlipid
reagent
conjug
biotin
fslbiotin
sigma
allow
incorpor
viral
membran
result
biotinyl
viral
particl
captur
onto
streptavidinco
plate
describ
previous
ng
et
al
plate
wash
block
bsapb
buffer
serial
dilut
antibodi
ad
virusco
plate
wash
solubl
flagtag
domain
c
protein
nm
ad
well
plate
wash
extent
bind
rvsvgp
cl
detect
use
antiflaghrp
horseradish
peroxidas
antibodi
conjug
incub
perform
hr
c
bind
express
percentag
maxim
bind
signal
obtain
noantibodi
control
kinet
experi
perform
fortebio
octet
platform
data
collect
c
orbit
shake
rpm
ml
protein
g
antihuman
fc
sensor
fortebio
equilibr
kinet
buffer
pb
bsa
min
prior
load
mgml
antibodi
min
stabl
baselin
establish
kinet
buffer
min
sensor
ad
rang
ebov
sudv
bdbv
gpdtm
concentr
associ
step
gpdtm
proceed
min
allow
gpdtm
dissoci
kinet
buffer
min
refer
sensor
without
use
account
nonspecif
bind
gp
sensor
data
fit
global
langmuir
bind
model
use
fortebio
data
analysi
softwar
mous
challeng
studi
ebov
femal
balbc
mice
week
old
purchas
charl
river
laboratori
mice
expos
ip
dose
pfu
mayinga
strain
maebov
suspend
pb
antibodi
deliv
indic
ip
dose
time
point
exposur
control
mice
treat
pb
left
untreat
mice
observ
daili
clinic
sign
diseas
includ
limit
reduc
groom
hypoact
group
weight
record
day
observ
increas
minimum
twice
daili
mice
exhibit
sign
diseas
moribund
mice
human
euthan
base
institut
anim
care
use
committe
iacuc
approv
criteria
mice
observ
minimum
day
exposur
mous
challeng
studi
sudv
ifnabr
mice
week
old
background
purchas
jackson
laboratori
upon
arriv
mice
hous
microisolat
cage
provid
chow
water
ad
libitum
mice
challeng
intraperiton
pfu
sudv
treat
indic
time
antibodi
ip
inject
mice
observ
daili
lethal
clinic
sign
diseas
moribund
mice
human
euthan
base
iacucapprov
criteria
guinea
pig
challeng
studi
femal
hartley
guinea
pig
week
old
g
purchas
charl
river
laboratori
randomli
assign
differ
group
guinea
pig
challeng
ip
dose
ld
gpaebov
volchkov
et
al
ld
gpasudv
wong
et
al
ml
dmem
mab
mab
cocktail
given
ip
dose
dpi
mg
individu
mab
mab
cocktail
ratio
mab
per
anim
control
group
given
ml
pb
anim
monitor
sign
diseas
surviv
weight
chang
day
surviv
monitor
addit
day
anim
research
use
mice
conduct
protocol
approv
us
armi
medic
research
institut
infecti
diseas
usamriid
iacuc
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
usamriid
facil
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
adher
principl
state
guid
care
use
laboratori
anim
challeng
studi
conduct
maximum
contain
anim
facil
guinea
pig
experi
perform
nation
microbiolog
laboratori
winnipeg
mb
canada
anim
experi
approv
anim
care
committe
canadian
scienc
center
human
anim
health
accord
guidelin
outlin
canadian
council
anim
care
rel
bind
mutant
affect
four
glycan
cap
glycosyl
site
shown
percent
bind
antibodi
wild
type
wt
gp
express
cell
determin
flow
cytometri
relat
figur
figur
locat
residu
whose
mutat
increas
mab
bind
tabl
plot
model
ebov
gp
trimer
monom
structur
residu
present
ebov
crystal
structur
gener
locat
indic
show
residu
shown
shade
yellow
shown
shade
red
except
cy
shown
orang
model
creat
overlay
avail
crystal
structur
ebov
pdb
id
sudv
pdb
id
relat
figur
unbound
fab
show
molecular
weight
mw
mw
trimer
shift
kd
kda
upon
bind
indic
bind
singl
fab
per
trimer
relat
figur
